For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 1,632,581 | |||
| General and administrative expenses | 10,279,981 | |||
| Total operating expenses | 11,912,562 | |||
| Loss from operations | -11,912,562 | |||
| Unrealized gain from changes in fair value of digital assets | 1,812,348 | |||
| Realized gain on sale of digital assets | 4,197,394 | |||
| Trading gains, net | 97 | |||
| Foreign currency gains/(losses), net | -521 | |||
| Change in fv of warrant liability | -22,377 | |||
| Change in fv of derivative | -55,146 | |||
| Interest income | 107,595 | |||
| Interest expense | 283,011 | |||
| Total other income (expense) | 5,911,425 | |||
| Net loss | -6,001,137 | |||
| Basic EPS | -0.55 | |||
| Diluted EPS | -0.55 | |||
| Basic Average Shares | 10,881,907 | |||
| Diluted Average Shares | 10,881,907 | |||
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)